All Outputs (16)

PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease (2023)
Journal Article
Nielsen, M. J., Dolman, G. E., Harris, R., Frederiksen, P., Chalmers, J., Grove, J. I., …Guha, I. N. (2023). PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease. JHEP Reports, 5(6), Article 100743. https://doi.org/10.1016/j.jhepr.2023.100743

Background & Aims: Fibroblast activity is a key feature of fibrosis progression and organ function loss, leading to liver-related complications and mortality. The fibrogenesis marker, PRO-C3, has been shown to have prognostic significance in relation... Read More about PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease.

Delivery of biannual ultrasound surveillance for individuals with cirrhosis and cured hepatitis C in the UK (2023)
Journal Article
Hamill, V., Gelson, W., MacDonald, D., Richardson, P., Ryder, S. D., Aldersley, M., …Innes, H. (2023). Delivery of biannual ultrasound surveillance for individuals with cirrhosis and cured hepatitis C in the UK. Liver International, 43(4), 917-927. https://doi.org/10.1111/liv.15528

Background: Previous studies show the uptake of biannual ultrasound (US) surveillance in patients with cirrhosis is suboptimal. Here, our goal was to understand in broader terms how surveillance is being delivered to cirrhosis patients with cured hep... Read More about Delivery of biannual ultrasound surveillance for individuals with cirrhosis and cured hepatitis C in the UK.

Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: Results from a genome-wide case-control study (2022)
Journal Article
Buch, S., Innes, H., Lutz, P. L., Nischalke, H. D., Marquardt, J. U., Fischer, J., …Stickel, F. (2022). Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: Results from a genome-wide case-control study. Gut, https://doi.org/10.1136/gutjnl-2022-327196

Objective: Hepatocellular carcinoma (HCC) often develops in patients with alcohol-related cirrhosis at an annual risk of up to 2.5%. Some host genetic risk factors have been identified but do not account for the majority of the variance in occurrence... Read More about Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: Results from a genome-wide case-control study.

The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis (2021)
Journal Article
Innes, H., Nischalke, H. D., Guha, I. N., Weiss, K. H., Irving, W., Gotthardt, D., …Buch, S. (2022). The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis. Hepatology Communications, 6(5), 1213-1226. https://doi.org/10.1002/hep4.1886

The host genetic background for hepatocellular carcinoma (HCC) is incompletely understood. We aimed to determine if four germline genetic polymorphisms, rs429358 in apolipoprotein E (APOE), rs2642438 in mitochondrial amidoxime reducing component 1 (M... Read More about The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis.

Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection (2021)
Journal Article
Innes, H., Jepsen, P., McDonald, S., Dillon, J., Hamill, V., Yeung, A., …Guha, I. N. (2021). Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection. JHEP Reports, 3(6), Article 100384. https://doi.org/10.1016/j.jhepr.2021.100384

Background & Aims: Hepatocellular carcinoma (HCC) prediction models can inform clinical decisions about HCC screening provided their predictions are robust. We conducted an external validation of 6 HCC prediction models for UK patients with cirrhosis... Read More about Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection.

aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis (2020)
Journal Article
Fan, R., Papatheodoridis, G., Sun, J., Innes, H., Toyoda, H., Xie, Q., …Hou, J. (2020). aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. Journal of Hepatology, 73(6), 1368-1378. https://doi.org/10.1016/j.jhep.2020.07.025

© 2020 European Association for the Study of the Liver Background & Aims: Hepatocellular carcinoma (HCC) is the leading cause of death in patients with chronic hepatitis. In this international collaboration, we sought to develop a global universal HC... Read More about aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis.

Nanopore sequencing from extraction-free direct PCR of dried serum spots for portable hepatitis B virus drug-resistance typing (2020)
Journal Article
Astbury, S., Nunes Soares, M. M. D. C., Peprah, E., King, B., Jardim, A. C. G., Shimizu, J. F., …McClure, P. (2020). Nanopore sequencing from extraction-free direct PCR of dried serum spots for portable hepatitis B virus drug-resistance typing. Journal of Clinical Virology, 129, Article 104483. https://doi.org/10.1016/j.jcv.2020.104483

© 2020 Background: Effective drug regimens for the treatment of hepatitis B virus (HBV) infections are essential to achieve the World Health Organisation commitment to eliminate viral hepatitis by 2030. Lamivudine (3TC) is widely used in countries wi... Read More about Nanopore sequencing from extraction-free direct PCR of dried serum spots for portable hepatitis B virus drug-resistance typing.

Testing for hepatitis C virus infection in UK prisons: what actually happens? (2019)
Journal Article
Jack, K., Thomson, B. J., & Irving, W. L. (2019). Testing for hepatitis C virus infection in UK prisons: what actually happens?. Journal of Viral Hepatitis, 26(6), 644-654. https://doi.org/10.1111/jvh.13071

Prisons are a key demographic in the drive to eradicate hepatitis C virus (HCV) as a major public health threat. We have assessed the impact of the recently introduced national opt-out policy on the current status of HCV testing in 14 prisons in the... Read More about Testing for hepatitis C virus infection in UK prisons: what actually happens?.

SOX9 regulated matrix proteins are increased in patients serum and correlate with severity of liver fibrosis (2018)
Journal Article
Athwal, V. S., Pritchett, J., Martin, K., Llewellyn, J., Scott, J., Harvey, E., …Hanley, K. P. (2018). SOX9 regulated matrix proteins are increased in patients serum and correlate with severity of liver fibrosis. Scientific Reports, 8(1), Article 17905. https://doi.org/10.1038/s41598-018-36037-4

Extracellular matrix (ECM) deposition and resultant scar play a major role in the pathogenesis and progression of liver fibrosis. Identifying core regulators of ECM deposition may lead to urgently needed diagnostic and therapetic strategies for the d... Read More about SOX9 regulated matrix proteins are increased in patients serum and correlate with severity of liver fibrosis.

Short-term changes observed in multi-parametric liver MRI following therapy with direct acting antivirals in chronic hepatitis C virus patients (2018)
Journal Article
Bradley, C., Scott, R., Cox, E., Palaniyappan, N., Thompson, B., Ryder, D., …Francis, S. (2019). Short-term changes observed in multi-parametric liver MRI following therapy with direct acting antivirals in chronic hepatitis C virus patients. European Radiology, 29(6), 3100–3107. https://doi.org/10.1007/s00330-018-5788-1

Methods: We applied multiparametric MRI to assess changes in liver composition, perfusion and blood flow in 17 patients before DAA therapy and after treatment completion (within 12 weeks of last DAA tablet swallowed). Results: We observed changes in... Read More about Short-term changes observed in multi-parametric liver MRI following therapy with direct acting antivirals in chronic hepatitis C virus patients.

Pretreatment lesions on magnetic resonance imaging in patients with hepatitis C virus infection diagnosed with hepatocellular carcinoma after initiating direct-acting antiviral therapy (2018)
Journal Article
Scott, R. A., Aithal, G. P., Francis, S. T., & Irving, W. L. (2018). Pretreatment lesions on magnetic resonance imaging in patients with hepatitis C virus infection diagnosed with hepatocellular carcinoma after initiating direct-acting antiviral therapy. Gastroenterology, 154(6), https://doi.org/10.1053/j.gastro.2017.12.047

Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease (2018)
Journal Article
Kendall, T., Dolman, G., Duff, C., Paish, E. C., Zaitoun, A., Irving, W. L., …Guha, I. N. (2018). Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease. Histopathology, 73(1), 90-100. https://doi.org/10.1111/his.13499

Aims. Needle biopsy remains essential for diagnosis in assessment of liver disease, although there remains associated risk. Examination is largely limited to subjective evaluation and biopsies are not exploited to provide personalised prognostic info... Read More about Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease.

SOX9 predicts progression towards cirrhosis in patients while its loss protects against liver fibrosis (2017)
Journal Article
Athwal, V. S., Pritchett, J., Llewellyn, J., Martin, K., Camacho, E., Raza, S. M., …Hanley, K. P. (in press). SOX9 predicts progression towards cirrhosis in patients while its loss protects against liver fibrosis. EMBO Molecular Medicine, 9(12), https://doi.org/10.15252/emmm.201707860

Fibrosis and organ failure is a common endpoint for many chronic liver diseases. Much is known about the upstream inflammatory mechanisms provoking fibrosis and downstream potential for tissue remodeling. However, less is known about the transcriptio... Read More about SOX9 predicts progression towards cirrhosis in patients while its loss protects against liver fibrosis.

Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK (2017)
Journal Article
Hudson, B., Walker, A. J., & Irving, W. L. (2017). Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK. Journal of Medical Virology, 89(12), 2158-2164. https://doi.org/10.1002/jmv.24848

© 2017 The Authors. Journal of Medical Virology Published by Wiley Periodicals, Inc. Designing services with the capacity and expertise to meet the needs of the chronic hepatitis C (CHC) population in the era of direct acting antivirals (DAAs), and w... Read More about Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK.

Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis (2016)
Journal Article
Foster, G. R., Irving, W. L., Cheung, M. C., Walker, A. J., Hudson, B. E., Verma, S., …Agarwal, K. (2016). Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. Journal of Hepatology, 64(6), 1224-1231. https://doi.org/10.1016/j.jhep.2016.01.029

© 2016 European Association for the Study of the Liver. Background & Aims All oral direct acting antivirals (DAAs) effectively treat chronic hepatitis C virus (HCV) infection, but the benefits in advanced liver disease are unclear. We compared outcom... Read More about Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.

Increasing uptake of hepatitis C virus infection case- finding, testing, and treatment in primary care: evaluation of the HepCATT (Hepatitis C Assessment Through to Treatment) trial (2009)
Journal Article
Horwood, J., Clement, C., Roberts, K., Waldron, C., Irving, W., Macleod, J., & Hickman, M. (2009). Increasing uptake of hepatitis C virus infection case- finding, testing, and treatment in primary care: evaluation of the HepCATT (Hepatitis C Assessment Through to Treatment) trial. Journal of Clinical Virology, 44(2), https://doi.org/10.3399/bjgp20x708785

Background Hepatitis C virus (HCV) infection is a key cause of liver disease but can be cured in more than 95% of patients. Around 70 000 people in England may have undiagnosed HCV infection and many more will not have been treated. Interventions to... Read More about Increasing uptake of hepatitis C virus infection case- finding, testing, and treatment in primary care: evaluation of the HepCATT (Hepatitis C Assessment Through to Treatment) trial.